Half of US-approved drugs unavailable to Japanese patients, study finds

Roughly half of drugs newly approved by the US Food and Drug Administration fail to reach Japanese patients, reflecting regulatory and market barriers that limit access to the latest treatments in one of the world's largest pharmaceutical markets.

The disparity highlights structural differences between American and Japanese drug approval systems. While the FDA operates under a relatively streamlined approval process, Japan's Pharmaceuticals and Medical Devices Agency faces stricter requirements and more extensive review periods, causing delays that can stretch years beyond US authorization.

Market considerations also play a significant role in the gap. Pharmaceutical companies often prioritize resource allocation to larger Western markets first, leaving smaller markets like Japan in a queue for regulatory submission and approval. Some manufacturers determine that the Japanese market does not justify the costs of navigating local approval requirements, choosing instead to focus on other regions.

The situation has prompted discussions among Japanese health authorities and industry stakeholders about streamlining approval mechanisms to reduce lag times. Policymakers have expressed concern that restricted access to innovative treatments may disadvantage Japanese patients and affect the competitiveness of the nation's healthcare system on the global stage.

Efforts to expedite the approval process, including closer alignment with international standards and accelerated review pathways for certain drug categories, are under consideration as Japan seeks to narrow the gap between US approvals and domestic availability.